Mycophenolate mofetil and cardiovascular disease
Publication
, Journal Article
Hughes, G; Phillips, H
Published in: Lupus
November 1, 2006
Lupus is proving a fertile ground for research into mechanisms of accelerated atheroma. Often referred to as 'the new diabetes', lupus has a relative risk of myocardial infarction way in excess of, for example, other inflammatory diseases such as rheumatoid arthritis. The possible suspects are discussed in this issue of LUPUS, with the antiphospholipid antibody family becoming increasingly important. The observation that mycophenolate mofetil might have therapeutic properties in some models of accelerated vascular disease has thus added impetus to studies of mofetil in lupus and related diseases.
Duke Scholars
Published In
Lupus
DOI
EISSN
1477-0962
ISSN
0961-2033
Publication Date
November 1, 2006
Volume
15
Issue
11_suppl
Start / End Page
1 / 2
Related Subject Headings
- Arthritis & Rheumatology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hughes, G., & Phillips, H. (2006). Mycophenolate mofetil and cardiovascular disease. Lupus, 15(11_suppl), 1–2. https://doi.org/10.1177/0961203306071672
Hughes, G., and H. Phillips. “Mycophenolate mofetil and cardiovascular disease.” Lupus 15, no. 11_suppl (November 1, 2006): 1–2. https://doi.org/10.1177/0961203306071672.
Hughes G, Phillips H. Mycophenolate mofetil and cardiovascular disease. Lupus. 2006 Nov 1;15(11_suppl):1–2.
Hughes, G., and H. Phillips. “Mycophenolate mofetil and cardiovascular disease.” Lupus, vol. 15, no. 11_suppl, Nov. 2006, pp. 1–2. Scopus, doi:10.1177/0961203306071672.
Hughes G, Phillips H. Mycophenolate mofetil and cardiovascular disease. Lupus. 2006 Nov 1;15(11_suppl):1–2.
Published In
Lupus
DOI
EISSN
1477-0962
ISSN
0961-2033
Publication Date
November 1, 2006
Volume
15
Issue
11_suppl
Start / End Page
1 / 2
Related Subject Headings
- Arthritis & Rheumatology
- 3202 Clinical sciences
- 1103 Clinical Sciences